Drug Trial Radar · NCT07798648
A Study of COVID-19 Vaccine(s) in Children and Adults
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
713
Actual
Start
Aug 31, 2026
Primary completion
Apr 12, 2027
Study completion Apr 12, 2027
Sponsor
- Lead sponsor
- BioNTech SEIndustry
- Sponsor type
- Industry
- Collaborators
- Pfizer
- First posted
- Sep 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 5 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the safety and effects of updated COVID-19 vaccines (called BNT162b2) in participants 5 Through 64 Years of Age with risk factors for Severe COVID-19, and Participants 65 Years of Age and Older. This study is seeking participants who: * are medically stable * have not had a recent COVID-19 infection or a recent COVID-19 vaccination * have not received certain routine vaccines recently * participants that are 5 through 64 years of age will need to have at least 1 medical condition that increase their risk of complications from COVID-19. Participants in Cohort 1 of this study will receive a single age-appropriate dose (30 mcg for participants aged ≥12 years; 10 mcg for participants aged 5-11 years) of BNT162b2 vaccine 1 which targets COVID-19 (2026/2027 recommended strain) injected in the upper arm. The study team and participants will know which injection they receive. Participants in Cohort 2 of this study will randomly receive 1 injection into their upper arm of either: BNT162b2 vaccine 1; BNT162b2 vaccine 2, or BNT162b2 vaccine 3 which targets COVID-19. The study team and participants will not know which injection they receive. Participants enrolled in Cohort 1 will be in the study for about 2 months and will have at least 3 scheduled visits. Participants enrolled in Cohort 2 will be in the study for about 6 months and will have at least 3 scheduled visits. Participants will record side effects and complete diaries following visit procedures. For Cohort 1 the study team will collect a nose swab and blood samples at 2 of the 3 visits. For Cohort 2 the study team will collect a nose swab and blood samples at all of the visits.
Conditions
- COVID-19 Vaccines
Interventions
BNT162b2Biological
BNT162b2 vaccine 1 (2026/2027 recommended strain)
BNT162b2Biological
BNT162b2 vaccine 2
BNT162b2Biological
BNT162b2 vaccine 3
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants reporting local reactions or systemic eventsTime frame: For up to 7 days after vaccination
- Percentage of participants reporting adverse eventsTime frame: From vaccination through 1 month after vaccination
- Percentage of participants reporting serious adverse eventsTime frame: From vaccination up to 6 months
- Geometric Mean Fold Rise (GMFRs)Time frame: From baseline through 1 month after vaccination
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
C & R Research Servcies USA, Inc.
Homestead, Florida
Indago Research & Health Center, Inc
Miami Lakes, Florida
AGILE Clinical Research Trials, LLC
Atlanta, Georgia
East-West Medical Research Institute
Honolulu, Hawaii
Kentucky Pediatric /Adult Research
Bardstown, Kentucky
Center for Immunization Research
Baltimore, Maryland
Dayton Clinical Research
Dayton, Ohio
Senders Pediatrics
South Euclid, Ohio
DM Clinical Research
Philadelphia, Pennsylvania
Cedar Health Research
Dallas, Texas
Cedar Health Research
Euless, Texas
DM Clinical Research-Cyfair
Houston, Texas
DM Clinical Research
Tomball, Texas
J. Lewis Research, Inc. / Foothill Family Clinic
Salt Lake City, Utah
J. Lewis Research, Inc. / Foothill Family Clinic South
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.